

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12531-002001	Application No. 09/722,096
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Ernest G. Hope	
		Filing Date November 22, 2000	Group Art Unit 1623 / 64

RECEIVED

SEP 17 2001

TECH CENTER 1600/290

## U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
CY	AA	5,660,827	08/26/97	Thorpe et al.			


## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB							

## Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
CY	AC	Antin, "Graft-Versus-Leukemia: No Longer an Epiphenomenon", <u>Blood</u> , 82:2273-2277 (1993)
CY	AD	Ayalon et al., "Induction of transporter associated with antigen processing by interferon $\gamma$ confers endothelial cell cytoprotection against natural killer-mediated lysis", <u>Proc. Natl. Acad. Sci. USA</u> , 95:2435-2440 (1998)
CY	AE	Hauch et al., "Anti-Leukemia Potential of Interleukin-2 Activated Natural Killer Cells After Bone Marrow Transplantation for Chronic Myelogenous Leukemia", <u>Blood</u> , 75:2250-2262 (1990)
CY	AF	Hoyle et al., "Expansion of Philadelphia Chromosome-Negative CD3+CD56+ Cytotoxic Cells From Chronic Myeloid Leukemia Patients: In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease Mice", <u>Blood</u> , 92:3318-3327 (1998)
CY	AG	Kolb et al., "Graft-Versus-Leukemia Effect of Donor Lymphocyte Transfusions in Marrow Grafted Patients", <u>Blood</u> , 86:2041-2050 (1995)
CY	AH	Kotasek et al., "Mechanism of Cultured Endothelial Injury Induced by Lymphokine-activated Killer Cells", <u>Cancer Research</u> , 48:5528-5532 (1988)
CY	AI	Lu et al., "A Novel Population of Expanded Human CD3+CD56+ Cells Derived from T Cells with Potent In Vivo Antitumor Activity in Mice with Severe Combined Immunodeficiency", <u>The Journal of Immunology</u> , 153:1687-1696 (1994)
CY	AJ	Martin et al., "Effects of In Vitro Depletion of T Cells in HLA-Identical Allogeneic Marrow Grafts", <u>Blood</u> , 66:664-672 (1985)
CY	AK	Mehta et al., "Two Pathways of Exocytosis of Cytoplasmic Granule Contents and Target Cell Killing by Cytokine-Induced CD3+CD56+ Killer Cells", <u>Blood</u> , 86:3493-3499 (1995)
CY	AL	Porter et al., "Induction of Graft-Versus-Host Disease as Immunotherapy for Relapsed Chronic Myeloid Leukemia", <u>The New England Journal of Medicine</u> , 330:100-106 (1994)
CY	AM	Rosenberg et al., "Regression of Established Pulmonary Metastases and Subcutaneous Tumor Mediated by the Systemic Administration of High-Dose Recombinant Interleukin 2", <u>J. Exp. Med.</u> 161:1169-1188 (1985)
CY	AN	Rosenberg et al., "Special Report, Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 In the Immunotherapy of Patients with Metastatic Melanoma", <u>The New England Journal of Medicine</u> , 319:1676-1680 (1988)
CY	AO	Scheffold et al., "Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia", <u>Stockton Press</u> , 33-39 (1994)

Examiner Signature <i>Christopher H. Y.</i>	Date Considered 12-4-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Sheet 2 of 2

TECH CENTER 1600/2900

SEP 17 2001

RECEIVED

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12531-002001	Application No. 09/722,096
	Applicant Ernest G. Hope		
	Filing Date November 22, 2000	Group Art Unit 1623	

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AP	Schmidt-Wolf et al., "Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma", <u>British Journal of Cancer</u> , 81:1009-1016 (1999)
	AQ	Schmidt-Wolf et al. "Activated T cells and cytokine-induced CD3+ CD56+ killer cells", <u>Ann Hematol</u> , 74:51-56 (1997)
CY	AR	Schmidt-Wolf et al., "Sensitivity of Multidrug-Resistant Tumor Cell Lines to Immunologic Effector Cells", <u>Cellular Immunology</u> , 169:85-90 (1996)
CY	AS	Schmidt-Wolf et al., "Clinical Protocol, Interleukin-7 Gene Transfer in Patients with Metastatic Colon Carcinoma, Renal Cell Carcinoma, Melanoma, or with Lymphoma", <u>Human Gene Therapy</u> , 5:1161-1168 (1994)
CY	AT	Siegel et al., "Interleukin-2 Toxicity", <u>Journal of Clinical Oncology</u> , 9:694-704 (1991)
CY	AU	Stoner et al., "Heritable germ and somatic cell lineage competitions in chimeric colonial protochordates", <u>Proc. Natl. Acad. Sci. USA</u> , 96:9148-9153 (1999)
CY	AV	Sullivan et al. "Influence of Acute and Chronic Graft-Versus-Host Disease on Relapse and Survival After Bone Marrow Transplantation From HLA-Identical Siblings as Treatment of Acute and Chronic Leukemia", <u>Blood</u> , 73:1720-1728 (1989)
CY	AW	Weiden et al., "Antileukemic Effect of Graft-Versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts", <u>The New England Journal of Medicine</u> , 300:1068-1073 (1979)
CY	AX	Zoll et al., "Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12", <u>Cancer Immunol. Immunother</u> , 47:221-226 (1998)
	AY	
	AZ	
	AAA	
	ABB	
	ACC	
	ADD	
	AEE	
	AFF	
	AGG	
	AHH	
	AII	
	AJJ	
	AKK	
	ALL	

Examiner Signature <i>Chris John H. Van</i>	Date Considered 12-4-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	